Chemotherapy

The addition of pembrolizumab to perioperative chemotherapy failed to significantly extend EFS among patients with locally advanced resectable gastric and gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.

CHICAGO — An electronic frailty index may help to predict risk for poor outcomes, including mortality, in patients undergoing chemotherapy.

Editor’s note: This is the first in a series of five stories from ASCO Voices, a session during ASCO Annual Meeting focused on the human side of oncology.

CHICAGO — Early cessation of chemotherapy as a result of intolerance had significant implications on pathologic response, OS and RFS in patients with muscle-invasive bladder cancer, according to a poster presentation at ASCO Annual Meeting.

Cancer centers in the United States continue to experience critical shortages of commonly used platinum-based chemotherapies, according to survey results from National Comprehensive Cancer Network.

CHICAGO — Erdafitinib improved OS, PFS and objective response rate compared with chemotherapy among patients with advanced or metastatic urothelial cancer with select fibroblast growth factor receptor alterations.

Amid an ongoing drug shortage, the FDA is allowing the chemotherapy drug cisplatin to be imported from China.

CHICAGO — A chemotherapy de-escalation strategy involving dual HER2 blockade resulted in high rates of 3-year invasive DFS among patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.

CHICAGO — The addition of toripalimab to first-line nab-paclitaxel significantly prolonged PFS among patients with PD-L1-positive metastatic or recurrent triple-negative breast cancer, according to results of a phase 3 trial.

CHICAGO — Administering modified FOLFIRINOX chemotherapy before chemoradiation, surgery and adjuvant chemotherapy improved survival outcomes of patients with locally advanced rectal cancer, according to results of the PRODIGE 23 trial.